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Abstract: Stem cells are undifferentiated cells that have the unique ability to self-renew and 
differentiate into many different cell types. Their function is controlled by core gene networks 
whose misregulation can result in aberrant stem cell function and defects of regeneration or 
neoplasia. HOX genes are master regulators of cell identity and cell fate during embryonic 
development. They play a crucial role in embryonic stem cell differentiation into specific lineages 
and their expression is maintained in adult stem cells along differentiation hierarchies. Aberrant 
HOX gene expression is found in several cancers where they can function as either oncogenes by 
sustaining cell proliferation or tumor-suppressor genes by controlling cell differentiation. Emerging 
evidence shows that abnormal expression of HOX genes is involved in the transformation of adult 
stem cells into cancer stem cells. Cancer stem cells have been identified in most malignancies and 
proved to be responsible for cancer initiation, recurrence, and metastasis. In this review, we consider 
the role of HOX genes in normal and cancer stem cells and discuss how the modulation of HOX 
gene function could lead to the development of novel therapeutic strategies that target cancer stem 
cells to halt tumor initiation, progression, and resistance to treatment. 
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1. HOX Genes are Master Regulators of Embryonic Development 
HOX genes encode evolutionarily conserved transcription factors that are expressed under 
temporal and spatial control to establish patterning and morphogenesis in the vertebrate embryo. 
They play a critical role during development, and either loss or gain of function of HOX genes can 
lead to homeotic transformation and abnormal formation of body structures [1]. In humans and mice, 
HOX genes are organized in four paralogous gene clusters (A, B, C, D) coding for 39 genes. Their 
expression is tightly controlled by their clustered organization so that their activation in the posterior 
part of the primitive streak occurs by a process of temporal and spatial collinearity depending on 
their location within the cluster. The position of HOX genes within the cluster corresponds to their 
positional expression along the anterior-posterior axis, with expression following the direction from 
the 3’ side (anterior) to the 5’ (posterior). Their temporal expression is also coordinated so that HOX 
genes positioned 3’ in the cluster are expressed earlier than those at the 5’ [2]. In addition, a 
phenomenon of posterior dominance can be observed whereby posterior genes are dominant with 
respect to more anterior genes when expressed in adjacent areas [3]. This coordinated expression is 
regulated by key developmental signals within the embryo, including Wnt ligands, retinoic acid 
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(RA), and fibroblast growth factor (FGF) [4,5]. Important upstream regulators of HOX gene 
transcription are CDX genes. These are direct targets of Wnt, RA, and FGF and therefore integrate 
signaling pathway networks to regulate HOX gene expression [4]. 
Different structural and epigenetic parameters have been described contributing to the 
collinearity of HOX gene expression. These include their chromosomal cluster organization, cis-
regulatory elements (enhancers and lncRNA), histone modifications, chromosome boundaries, and 
3D chromatin conformation [6]. During development, the regulation of HOX genes is achieved by 
methylation of Histone H3 residues by Trithorax (TrxG) and Polycomb (PcG) group proteins, which 
establish the active H3K4me3 and repressive H3K27me3 marks, respectively. These epigenetic 
modifiers create bivalent domains and a poised state in the pre-gastrulating embryo by 
transcriptional control of developmental genes. In the bivalent state, H3K27me3 is dominant over the 
H3K4me3 mark, with genes controlled by these marks being repressed as default [7]. The removal of 
H3K27me3 by histone demethylases then allows the prompt expression of patterning and lineage 
specifier HOX genes following a temporal and special collinearity [8,9]. At gastrulation, 
trimethylation of H3K27 mediated by the Polycomb Repressive Complex 2 (PRC2) and recruitment 
of the Polycomb Repressive Complex 1 (PRC1) induce chromatin condensation to maintain a 
permanent silencing of the HOX genes in a lineage-specific manner [9,10]. The silencing of non-
lineage tissue specific genes can then be further reinforced by DNA methylation, a stable and 
heritable epigenetic mark [11,12]. Therefore, during cell fate determination the chromosomal 
domains marked by active H3K4 or silent H3K27 methylation are mutually exclusive and are 
programmed to establish the HOX code and epigenetic memory of differentiated cells [13]. Together 
with the epigenetic regulation mediated by PcG and TrxG proteins, intergenic transcription of 
miRNA and long non-coding RNAs (lncRNA) regulate the expression of HOX genes. HOTAIR, 
HOTAIRM1, and HOTTIP are lncRNA located in the cluster, and they have been shown to configure 
the epigenetic profile of the HOX loci by association with PcG and TrxG proteins and to control gene 
expression either in cis or in trans [14]. For instance, the lncRNA HOTAIR is located in the HOXC 
cluster and required for the silencing of HOXD genes through interaction with the PRC2 complex 
and for the establishment of the repressive H3K27me3 mark [14]. On the other hand, HOTAIRM1 is 
a lncRNA located within the HOXA cluster that plays a role in regulating the expression of 3’ HOXA 
genes by preventing the accessibility of the lysine-specific demethylase 6A (UTX) and by delaying 
the expression of central genes in the cluster. The 5’ HOXA genes are instead regulated by the lncRNA 
HOTTIP, which is located upstream of HOXA13 [15]. As a result of their epigenetic regulation, HOX-
coded transcription factors can act as either transcriptional activators or repressors of target genes. 
These consist of factors that regulate diverse biological processes and include a network of 
transcription factors, signaling molecules, components of signaling pathways, and “realizator” genes 
that are directly involved in cell differentiation and tissue organization [16,17]. The diversity and 
specificity of HOX proteins is realized by their interaction with cofactors that belong to the TALE 
family. These include the PBC and MEINOX classes of transcription factors, with the PBC family 
comprising PBX proteins (PBX1-4) and the MEINOX family including MEIS (MEIS1-3) and PREP 
(PRE1-2) proteins. All of these transcription factors cooperate with HOX proteins by forming 
heteromeric complexes, [18,19] and their diverse and context-dependent interaction regulates cell fate 
decisions and specific cell functions during embryo patterning and morphogenesis. 
2. HOX Genes and Cellular Identity 
The concerted actions of HOX proteins and their cofactors are responsible not only for HOX gene 
homeotic function, but also for regulation of organogenesis. In this process, the function of HOX 
genes is to control cell proliferation, differentiation, migration, and apoptosis [16]. The resulting 
embryonic HOX gene expression profiles in each body region are then sustained in the adult so that 
cell and tissue characteristics are maintained according to a specific “HOX code” [20]. 
At the cellular level, the primary role of HOX genes is to regulate cell specification and tissue 
differentiation. During embryogenesis, the expression of HOX genes maintains positional 
information, and it is epigenetically inherited so that cells can maintain a memory of their identity 
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during the lifetime of an organism. A significant demonstration of the role played by HOX genes in 
the regulation of cell identity is provided by their expression pattern in adult human fibroblasts. In 
these cells, HOX gene expression can predict their original embryonic position along the 
developmental axes [21,22]. For instance, the expression of HOXA and HOXD genes reflects the 
location along the proximal and distal axis of the limbs, whereas HOXC genes correlate with the 
anterior and posterior axis of the trunk. HOXB genes are instead associated with fibroblasts of non-
dermal origin [22]. The same feature of positional identity is applicable to HOX gene expression 
profiles in smooth and skeletal muscle cells [23,24]. 
The expression of HOX proteins in different tissues, or in the same tissue at different anatomical 
locations, maintains correct cell identities during differentiation. Indeed, it has been demonstrated 
that HOX genes play a crucial role in stem cells both in embryonic and in adult tissues by controlling 
lineage specification, differentiation, and tissue maturation [25]. 
3. HOX Genes in Embryonic Stem Cells 
HOX genes are not expressed before gastrulation, and they are not transcribed in embryonic 
stem cells (ESC) derived from the inner cell mass of a blastocyst [26]. ESC are pluripotent cells that 
can differentiate into all of the different cell types that comprise the body. HOX genes in ESC are 
regulated by bivalent chromatin domains so that they are poised for activation after differentiation. 
As a result, the coverage of the polycomb complex PRC2 in ESC is not as extensive as in differentiated 
cells with silenced HOX gene expression [27]. ESC present an active epigenetic repression of HOX 
genes in their undifferentiated state, with HOX gene activation being induced upon differentiation 
[28]. At this stage, histone demethylases remove the repressive H3K27me3 mark from HOX lineage 
specifier genes, whilst PcG proteins maintain cell identity through transcriptional repression of HOX 
genes that are specific to other lineages [29,30]. In the mouse, Wnt3 induces the gradual and collinear 
activation of the HOX gene cluster during gastrulation [31]. This mechanism is recapitulated in 
differentiating mouse epiblast stem cells with concomitant activation of Cdx2 [32] and in human 
induced pluripotent stem cells with induction of a posterior mesoderm phenotype [33]. 
RA is another key inducer of HOX gene expression during ESC differentiation. RA treatment of 
ESC can significantly increase the induction of neural differentiation and upregulate the expression 
of HOX genes [34]. RA responsive elements (RARE) are found in the regulatory regions of many HOX 
genes which respond to RA signaling in a collinear fashion, with genes at 3’ responding to the signal 
more rapidly than those at the 5’ of the cluster [35,36]. RA receptor γ is essential for RA-induced 
activation of HOX gene transcription. Indeed, knockdown of RA receptor γ in mouse ESC impairs 
differentiation and reduces the expression of Hoxa and Hoxb cluster genes as well as the expression 
of their cofactors Pbx1 and Meis1 [37]. Importantly, RA/ RA receptor γ signaling is required to remove 
PcG repressive marks from most bivalent HOX gene regulatory regions during ESC differentiation 
via recruitment of the H3K27me3 demethylase UTX-KDM6A [34,38,39]. Specific HOX genes are 
involved in the control of cell fate specification and differentiation of ESC into different lineages. For 
instance, inducible expression of Hoxb1 in mouse ESC can induce the differentiation and expansion 
of posterior neural stem/progenitor cells [40]. On the other hand, HOXB4 acts as a master regulator 
of hematopoietic differentiation in both mouse and human pluripotent stem cells [41–43]. Hoxb4 can 
in fact regulate multiple transcription factors involved in hematopoiesis and chromatin modifiers, 
thus playing a role in establishing the epigenetic landscape of the developing hematopoietic 
stem/progenitor cells [41]. Finally, Hox6 gene paralogues (Hoxa6, Hoxb6, Hoxc6) control the 
differentiation of mouse ESC into insulin producing pancreatic cells [44]. Therefore, the role of HOX 
genes during embryonic development is mirrored in ESC and their expression allows the control of 
ESC differentiation to the three germ layers. 
4. HOX Genes in Adult Stem Cells 
The positional identity provided by HOX gene expression during development and 
differentiation into adult tissues provides a mechanism for imposing cell identity and fate restriction. 
This information is maintained in adult stem cells (ASC) and along their differentiation hierarchies. 
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This mechanism can be clearly observed in mesenchymal stem cells (MSC). These cells, isolated from 
different tissues including the bone marrow and adipose tissue, can differentiate to fat, bone, and 
cartilage. Despite their phenotypic similarity, MSC derived from different tissues present a profile of 
HOX gene expression that mirrors that of their developmental origin. The topographical specificity 
of HOX genes in MSC is also maintained after differentiation, indicating that HOX genes play a role 
in the specification of MSC identity [45,46]. Indeed, umbilical cord MSC (UC-MSC) and bone marrow 
MSC (BM-MSC) show a different profile of HOX gene expression. HOXA9, HOXB7, HOXC10 and 
HOXD6 are expressed in UC-MSC, whereas BM-MSC express HOXB7 and HOXD6 [47].  
Patterns of HOX gene expression can also distinguish stem cell populations of functionally 
distinct tissues and influence their differentiation potential. For instance, the HOX code of skeletal 
stem/progenitor cells (SSC) can affect their differentiation into resident tissue osteoblasts. These stem 
cells show a HOX gene expression profile based on their embryonic origin. Therefore, mouse SSC in 
the tibia maintain their embryonic identity being of mesodermal origin and expressing Hoxa1. On the 
other hand, those in the mandibular originate from the neural crest and do not express HOX genes. 
This positional memory has been shown to affect the differentiation and regeneration potential of 
SSC when ectopically transplanted as the original HOX code is retained upon transplantation [48]. A 
similar behavior can be observed in two populations of cord blood stem cells, the UC-MSC and the 
unrestricted somatic stem cells (USSC). In contrast to UC-MSC, USSC do not express HOX genes, and 
therefore they retain the potential to differentiate into three germ layers similarly to ESC [47]. 
HOX genes also play a critical role in lineage restriction, as shown during the differentiation of 
the hematopoietic system. In this lineage, HOXA9, HOXB3, and HOXB4 are expressed in 
hematopoietic stem cells (HSC) which can differentiate into myeloid cells predominantly expressing 
HOXA genes, and erythroid and lymphoid cells expressing HOXB and HOXC genes, respectively 
[49,50]. HOX genes are also involved in the differentiation of other lineages. For example, HOXA10 
mediates osteogenic differentiation [51], whereas Hoxa3 and Hoxd3 induce differentiation of 
endothelial cells and angiogenesis in the mouse [52]. In the nervous system, 3’ HOX genes play a 
dominant role in neurogenesis and HOXB4 can drive neural differentiation in the neural tube, 
whereas Hoxb1 is essential for driving mouse neural stem cells to hindbrain [53]. Finally, several 
studies demonstrated a role for HOX genes in the regulation of terminal differentiation and tissue 
maturation. For instance, HOXA5 and HOXD10 are required for maintaining differentiated 
endothelial cells in a mature and quiescence state [28]. Similarly, Hoxa2 and Hoxb1 regulate the 
maturation of facial nerves in the mouse [54]. Although these studies suggest a positive effect of HOX 
gene expression during terminal differentiation, final tissue maturation can also require 
downregulation of HOX gene expression. This is the case for mature bone marrow cells that require 
downregulation of HOX genes specifying the hematopoietic lineage in order to terminally 
differentiate [49]. Altogether, these studies show the importance of the HOX code in maintaining ASC 
function and restriction of differentiation programs.  
5. HOX Genes in Cancer Stem Cells  
The fidelity of HOX gene expression in stem cells and their differentiated progenies is critical 
for normal tissue homeostasis. Consequently, alteration of HOX gene expression can play a critical 
role in the development of cancer [55]. HOX genes are frequently deregulated in cancer and many 
studies have shown they can function as tumor modulators by playing either an oncogenic or a tumor 
suppressive role [56]. Indeed, upregulation of HOX genes that are normally expressed in 
undifferentiated cells drives oncogenesis, whereas downregulation of HOX genes that are normally 
expressed in differentiated tissues results in the abolition of their function as tumor suppressors [57]. 
An altered expression of defined HOX clusters is found in different cancers, including alteration of 
HOXA genes in breast and cervical cancers, HOXB in colon cancer, HOXC in prostate and lung 
cancers, and HOXD in colon and breast cancer [58,59]. The involvement of HOX genes in cancer is 
therefore complex, with mechanisms of deregulation of specific HOX genes differing among cancer 
types [55]. 
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The role of HOX genes in maintaining cell identity limits the ability of cells to transition between 
different phenotypes. However, research on HOX genes during regeneration and wound healing in 
lower organisms have highlighted a role for these transcription factors in dedifferentiation and in 
shifting cells between metastable states. Therefore, aberrant HOX gene expression can lead to loss of 
differentiation and increased cell plasticity in the context of regeneration [60]. 
In cancer, this type of phenotypic plasticity can drive cells to re-acquire self-renewal and a stem 
cell phenotype, thus leading to the formation of cancer stem cells (CSC) and tumor initiation [12]. 
CSC are malignant stem/progenitor cells that have been identified in many different tumor types 
[61,62]. They can originate from transformation of normal tissue-resident stem/progenitor cells or 
reprogramming of differentiated cells [63,64]. Irrespective of their origin, CSC retain a high degree of 
plasticity and the ability to both proliferate and give rise to the heterogeneous bulk of the tumor in 
response to signals from the tumor microenvironment. CSC are involved in tumor initiation, 
progression, invasion, resistance to treatment and are directly linked to poor clinical outcome [65–67]. The 
formation of CSC involves the acquisition of a similar epigenetic landscapes to that of normal stem 
cells [12], with bivalent chromatin marks and DNA methylation dynamically regulating 
differentiation and stemness genes [68]. 
Aberrant epigenetic regulation of HOX gene expression is common in cancer and can contribute 
to CSC plasticity [69]. By screening homeobox gene expression in breast CSC, we demonstrated that 
epigenetic silencing of HOXC8 mediated by MIR-196 and DNA methylation induces a CSC 
phenotype in normal mammary stem cells, and it results in their increased self-renewal, impaired 
differentiation, and augmented tumorigenic potential [70]. A similar phenomenon was observed in 
other types of CSC. Epigenetic alteration of HOXD9 and HOXA10 in glioma CSC induces cell 
proliferation and survival [71,72]. Similarly, hypomethylation of the RA-cis regulatory element in 
leukemic stem cells induces expression of HOXB cluster genes driving the expansion of the malignant 
HSC pool [73]. Epigenetic regulation through expression of HOX-derived lncRNA can also influence 
the function of CSC [74]. HOTAIR expression can regulate the process of epithelial-to-mesenchymal 
transition (EMT) and acquisition of a CSC phenotype. HOTAIR sustains EMT induced by TGFβ in 
colon CSC [75], and it suppresses the tumor suppressor activity of MIR-7 via regulation of HOXD10 
whilst sustaining the expression of genes inducing EMT in breast CSC [76]. HOTAIR plays an 
important role in the transformation of CSC also in lung, liver, and brain cancers [77–79]. HOTTIP, 
another lncRNA derived from the HOX cluster, has also been shown to be involved in CSC function. 
In pancreatic cancer, HOTTIP enhances CSC properties by induction of HOXA9 and activation of the 
Wnt pathway [80]. 
Further studies have shown the role of HOX genes in CSC transformation. For instance, HOXA4 
and HOXA9 are enriched during the transformation of colon CSC, and their expression contributes 
to sustained CSC self-renewal [81]. Upregulation of HOXA9 has also been shown to sustain the self-
renewal of HSC in acute myeloid leukemia (AML) and the NUP98-HOXA9 fusion protein induces 
long-term proliferation and impaired differentiation of leukemic CSC [82,83]. In the breast, HOXB3 
has been shown to sustain the proliferation and drug resistance of breast CSC [84]. Finally, 
downregulation of HOXA5 and RA signaling in mammary cells leads to loss of the epithelial 
phenotype and acquisition of CSC characteristics [85]. HOXA5 plays a similar role in colon cancer, as 
silencing of HOXA5 by Wnt signaling maintains the pool of CSC and reactivation of HOXA5 by RA 
treatment induces loss of the CSC (Table 1) [86]. 
Table 1. HOX genes and HOX-cluster derived lncRNA in CSC. 
HOX Genes and 
lncRNA CSC Type Function 
HOXA5 
Breast Silencing of HOXA5 induces loss of differentiation [85] 
Colon Silencing of HOXA5 maintains the pool of CSC [86] 
HOXA4 Colon Expression of HOXA4 induces CSC self-renewal [87] 
HOXA9 AML HOXA9 and NUP98-HOXA9 fusion protein sustain self-renewal and 
impair differentiation of CSC [82,83] 
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Colon Expression of HOXA9 induces CSC self-renewal [87] 
HOXA10 Glioblastoma Activation of HOXA10 by the TrxG protein MLL induces 
tumorigenicity of CSC [72] 
HOXB cluster Leukemia Expression of HOXB genes induces expansion of CSC [73] 
HOXB3 Breast Expression of HOXB3 sustains proliferation of drug resistance of CSC 
[84] 
HOXC8 Breast 
Silencing of HOXC8 sustains self-renewal and impairs differentiation 
of CSC [70] 
HOXD9 Glioma Silencing of HOXD9 induces self-renewal and survival of CSC [71] 
HOTAIR 
Colon Expression of HOTAIR induces EMT and stemness [75] 
Breast 
Expression of HOTAIR induces EMT and stemness through activation 
of HOXD10 [76] 
Lung Expression of HOTAIR induces EMT and stemness [78] 
Liver Expression of HOTAIR induces EMT and stemness [77] 
Glioma Expression of HOTAIR induces proliferation and invasion of CSC [79] 
HOTTIP Pancreas Expression of HOTTIP induces CSC proliferation by induction of 
HOXA9 [80] 
Overall, the mentioned studies show a clear role of HOX genes in CSC function; however, the 
functional gene networks downstream of HOX activation still needs to be fully determined. 
The deregulation of HOX genes has an impact on key processes that sustain CSC function, 
including self-renewal, cell death evasion, and the ability to metastasize. HOX genes can sustain cell 
proliferation via autocrine stimulation by growth factors and stimulation of cell cycle progression 
and resistance to cell death [88]. For example, HOXB7 activates the FGF-MAPK (fibroblast growth 
factor- mitogen-activated protein kinases) and PI3K/Akt (phosphoinositide 3-kinase/ protein kinase 
B) signaling pathways in breast and gastric cancer, respectively [89,90]. Other HOX genes have a 
direct effect on cell cycle progression by inducing expression of Cyclin D1, like HOXB7 in colorectal 
cancer [91] and HOXA9 in leukemia [92]. HOX genes are also involved in the acquired resistance to 
cell death. Indeed, HOXB7 can induce resistance to cytotoxic drugs [93,94], and loss of HOXA5 results 
in resistance to apoptosis induced by TP53 in breast cancer [95]. 
Another important CSC characteristic regulated by HOX genes is invasion and metastasis. 
Several HOX genes are involved in the regulation of EMT, a process involved in metastatic spread 
and acquisition of CSC characteristics. This role has been demonstrated for HOXB7 which promotes 
EMT in breast cancer [89], and for HOXA10 whose silencing induces EMT in endometrial and lung 
cancer [96,97].  
6. HOX Genes and CSC Targeted Therapies 
Therapeutic targeting of CSC is a growing area of research, with drug discovery programs aimed 
at finding specific therapies that can eradicate this tumor initiating and disseminating cell population. 
Current evidence supports an important role played by HOX genes in the regulation of both normal 
and CSC function. Therefore, HOX genes may represent novel cancer biomarkers for targeted therapy 
and prediction of drug response and prognosis. Although targeting HOX genes represents an exciting 
opportunity, many challenges remain. First, transcription factors are not easily “druggable”. 
Targeting these proteins is difficult, mainly due to their intracellular or nuclear localization and their 
interaction with different cofactors [98]. This limitation could be overcome by developing targeted 
gene editing approaches coupled with novel drug delivery systems, and this certainly represents a 
new avenue with a great potential. 
Another possibility would be to interfere with targets downstream of the HOX genes. This 
approach is also particularly important when considering the functional versatility of HOX genes. As 
previously discussed, the same HOX gene can play different roles by functioning either as an 
oncogene or a tumor suppressor in different cancer types. In addition, some HOX genes with 
conserved patterning function present a high degree of redundancy, and therefore the inhibition of 
one gene can be overcome by expression of a paralogous gene or another gene in the same cluster 
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[99,100]. Targeting the interaction of HOX proteins with their cofactors PBS or MEIS could have the 
potential to inhibit the oncogenic potential of HOX genes in a specific cellular context. The inhibition 
of HOX–PBX complexes has already been achieved by using the antagonist peptide HXR9 which can 
induce apoptosis in a number of cancers, including solid tumors of the breast, prostate, ovarian, 
kidney, skin, lung, and blood tumors such as myeloma and AML [101]. 
Although these approaches seem promising, therapeutic targeting of CSC remains a clinical 
challenge, mainly due to their inherent plasticity that is influenced by the tumor microenvironment. 
Therefore, strategies aimed at targeting the microenvironment as well as CSC could prove effective. 
For example, HOXA5 and HOXD10 are expressed in normal epithelial and endothelial cells in the 
breast and their silencing is associated with CSC expansion and cell migration. Restoring the 
expression of both HOX genes could therefore be more effective and limit plasticity by targeting both 
CSC and angiogenesis [102–104]. 
Epigenetic therapies could also be instrumental for targeting HOX gene expression in CSC and 
affect their function by reducing self-renewal and promoting differentiation [105]. This approach is 
viable as several histone demethylase and histone deacetylase inhibitors are already clinically 
approved and many are currently being tested in clinical trials. Differentiation therapy approaches 
are also effective in targeting CSC by re-establishing normal HOX gene expression. RA can induce 
terminal differentiation of CSC, and it is currently used as standard of care for the treatment of acute 
promyelocytic leukemia [106]. We have also shown that RA is effective in re-establishing HOXC8 
expression in breast CSC [70], and other studies demonstrated the same effect in restoring expression 
in HOXA5 in colon and breast CSC [85,86]. 
HOX gene expression could also inform cancer prognosis given that cancers that are enriched 
with CSC are also associated with a worse patient outcome. An association between HOX expression 
and poor prognosis has already been established for breast cancer and lung adenocarcinoma 
(HOXB7), renal clear cell carcinoma (HOXC11), mesothelioma (HOXB4), oral squamous cell 
carcinoma (HOXD13), gastric cancer (HOXC6), thyroid cancer (HOXC10), bladder cancer (HOXB13), 
and AML (HOXA9) [101]. In addition, HOX gene expression profiling in circulating CSC could 
provide a powerful prognostic tool for the development of personalized therapies [107]. We have 
shown that HOX gene profiles in CSC defines breast cancer molecular subtypes, suggesting that their 
expression could be used as a blueprint for defining the cell of origin of different types of cancer and 
inform clinical decisions [70]. 
7. Conclusions 
HOX genes are considered master regulators of cell fate determination during embryonic 
patterning. Positional and cell-specific HOX identities established during development are 
maintained during adulthood and enable tissue homeostasis. A specific HOX code is concealed in 
adult stem cells, which allows their self-renewal and differentiation potential. This code is then 
resolved during differentiation into different lineages, resulting in tissue-specific expression of HOX 
genes. In cancer, erasure of the HOX code causes a loss of cell identity and acquisition of a 
transformed phenotype and CSC characteristics (Figure 1). Current evidence supports a role of HOX 
genes in the function of normal and cancer stem cells, but the molecular mechanisms by which HOX 
gene deregulation alters stem cell function are still not fully known. Therefore, large scale genomic 
and proteomic approaches are needed to elucidate the function of HOX genes and their mode of 
action in regulating stem cells in normal and cancerous tissues. Given the critical role of HOX genes 
in lineage specification and acquisition of cell identity, HOX profiles could allow the development of 
new diagnostic and prognostic tools for personalized clinical management of cancer patients. In 
addition, they could be used to devise targeted therapies that could eliminate the so far elusive CSC. 
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Figure 1. Role of HOX genes in the regulation of normal and cancer stem cells. HOX genes in ESC and 
ASC are epigenetically regulated by PcG and TrxG proteins. These epigenetic marks maintain stem 
cell identity and allow the expression of HOX genes in stem cells to regulate self-renewal and 
differential potential. After differentiation, lineage restriction is maintained by PcG proteins and DNA 
methylation. Genetic and epigenetic alterations induce reprogramming and EMT in either ASC or 
differentiated cells to induce their transformation into CSC. Re-expression of embryonic HOX genes 
and silencing of differentiation-specific genes drive CSC tumorigenicity and increase CSC plasticity. 
Abbreviations: ESC: embryonic stem cells; ASC: adult stem cells; PcG: Polycomb group of proteins; 
TrxG: Trithorax group of proteins; EMT: epithelial-to-mesenchymal transition; CSC: cancer stem cells. 
Author Contributions: Conceptualization, C.A.; writing—C.A.; writing—review and editing, J.S, A.Z, C.A; 
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